CUE Stock Summary and Trading Ideas (Cue Biopharma | NASDAQ:CUE)

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.

As of November 6, 2026, CUE stock price climbed to $18.73 with 205,140 million shares trading.

CUE has a beta of 4.82, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.11 to the broad based SPY ETF.

CUE has a market cap of $136.06 million. This is considered a Micro Cap stock.

Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.

In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.

The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, AVSC, AVTM.

CUE has underperformed the market in the last year with a return of -12.8%, while the SPY ETF gained +10.8%. In the last 3 month period, CUE fell short of the market, returning -30.7%, while SPY returned -4.1%. However, in the most recent 2 weeks CUE has outperformed the stock market by returning +0.4%, while SPY returned -3.2%.

CUE support price is $16.21 and resistance is $19.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.